Supplementary Table 6. Differences between favorable and unfavorable 3 months outcome in ischemic stroke patients (n=149)

Variable	3-month mRS 0–2 (n=57, 38.3%)	3-month mRS 3–6 (n=92, 61.7%)	Descriptive P
Female sex	24 (42.1)	53 (57.6)	0.066[†]
Age (yr)	76 (72–81)	82 (76–87)	<0.001[§]
Body weight (kg)	80 (69–90) 57 (100)	74 (65–82) 87 (94.6)	0.002[§]
Large vessel occlusion (ICA, MCA [1-3], PCA, ACA, BA)	24 (42.1)	45 (48.9)	0.418[†]
Recanalisation therapy	22 (38.6)	34 (37.0)	0.841[†]
Time of ischemic stroke (00:00–07:59)*	8 (18.6)	13 (15.9)	0.696[§]
Time of ischemic stroke (8:00–15:59)*	22 (51.2)	47 (57.3)	0.511[§]
Time of ischemic stroke (16:00–23:59)*	13 (30.2)	22 (26.8)	0.687[§]
Functional impairment			
Admission NIHSS	3 (1–7)	11 (5–19)	<0.001[§]
Premorbid mRS	1 (0–1)	3 (1–3)	<0.001[§]
Comorbidities			
Arterial hypertension	53 (93.0)	81 (88.0)	0.330[†]
Diabetes	13 (22.8)	31 (33.7)	0.157[†]
Hypercholesterolemia	33 (57.9)	46 (50.0)	0.348[†]
Previous stroke or TIA	15 (26.3)	33 (35.9)	0.225[†]
Congestive heart failure	13 (22.8)	19 (20.7)	0.756[†]
Vascular disease	29 (50.9)	50 (54.3)	0.680[†]
Atrial fibrillation	52 (91.2)	85 (92.4)	0.800[†]
Premorbid CHA_2DS_2-VASc score	4 (3–6)	5 (4–6)	0.009[§]
Creatinine at admission (mg/dL)	0.88 (0.74–1.10)	0.94 (0.73–1.15)	0.537[§]
eGFR (mL/min)[†]	67.56 (56.4–82.2) 43 (75.4)	59.24 (41.6–82.1) 76 (82.6)	0.018[§]
Pharmacotherapy			
Time between last DOAC intake and admission (min)	496 (249–869)	650 (409–952)	0.162[§]
Time between DOAC intake and event (min)*	420 (180–720)	480 (236–698)	0.035[§]
Low DOAC exposure	36 (63.2)	65 (70.7)	0.341[†]
Low DOAC concentration at event*	22/43 (51.2)	42/82 (51.2)	0.995[†]
Non-adherence	4 (7.0)	12 (13.0)	0.031[†]
Prescription quality			
DOAC adherence to SmPCs: underdosed	13 (22.8)	27 (29.3)	0.381[†]
DOAC adherence to SmPCs: correctly dosed	43 (75.4)	61 (66.3)	0.238[†]
DOAC adherence to SmPCs: overdosed	1 (1.8)	4 (4.3)	0.393[†]

Values are presented as number (%) or median (interquartile range).

mRS, modified Rankin Scale; ICA, internal carotid artery; MCA (1-3), middle cerebral artery (segments 1-3); PCA, posterior cerebral artery; ACA, anterior cerebral artery; BA, basilar artery; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack; eGFR, estimated glomerular filtration rate; DOAC, direct oral anticoagulant; SmPC, recommended doses from summaries of product characteristic.

*Concentration subgroup only (n=125); [†]eGFR according to Cockcroft-Gault formula; [‡]Chi-square; [§]t-test.